Statement of Changes in Beneficial Ownership (4)
31 January 2015 - 6:34AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Begley Colin Glenn
|
2. Issuer Name
and
Ticker or Trading Symbol
TETRALOGIC PHARMACEUTICALS CORP
[
TLOG
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Scientific Officer & SVP
|
(Last)
(First)
(Middle)
C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/28/2015
|
(Street)
MALVERN, PA 19355
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option
|
$5.25
|
1/28/2015
|
|
A
|
|
100000
|
|
(1)
|
1/28/2025
|
Common Stock
|
100000
|
$5.25
|
173705
|
D
|
|
Restricted Stock Unit
|
(2)
|
1/28/2015
|
|
A
|
|
75000
|
|
(2)
|
1/28/2018
|
Common Stock
|
75000
|
$0.00
|
0
|
D
|
|
Explanation of Responses:
|
(
1)
|
Beginning January 28, 2015, stock options will vest and become exercisable at 2% per month until fully vested. Stock options are subject to the reporting person's continued service as of each vesting date.
|
(
2)
|
Each restricted stock unit represents a contingent right to receive one share of TetraLogic Pharmaceuticals Corporation common stock. All 75,000 restricted stock units shall vest on January 28, 2018. Restricted stock units are subject to the reporting person's continued service as of the vesting date.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Begley Colin Glenn
C/O TETRALOGIC PHARMACEUTICALS CORP
343 PHOENIXVILLE PIKE
MALVERN, PA 19355
|
|
|
Chief Scientific Officer & SVP
|
|
Signatures
|
/s/ Richard L. Sherman, Attorney-In-Fact for Colin Glenn Begley
|
|
1/30/2015
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jun 2024 to Jul 2024
TetraLogic Pharmaceuticals (CE) (USOTC:TLOG)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about TetraLogic Pharmaceuticals Corporation (CE) (OTCMarkets): 0 recent articles
More Tetralogic Pharmaceuticals Corp News Articles